In partnership with Calcilytix Therapeutics, the DetectHypopara program provides physicians with access to no-cost genetic testing for patients, who have a clinical diagnosis of non-surgical hypoparathyroidism or hypocalcemia suspected to be of genetic cause, or meet other eligibility criteria for testing. This program is available for patients and providers in the US & Canada.
This test is a companion diagnostic device intended to select adult and pediatric patients 6 years of age and older who have obesity and certain variants in POMC/PCSK1/LEPR genes for treatment with IMCIVREE® (setmelanotide) in accordance with the approved therapeutic product labeling.
